XNCR - Stemline Therapeutics: Post-ASH Update For This Leader In The CD123 Space
Shares of Stemline Therapeutics (STML) have lost a third of their value since my August article recommended buying shares given the fact that the Q2 report showed progress on multiple fronts.
Recently, at the ASH (American Society of Hematology) annual meeting, the company unveiled promising data from early-stage studies of ELZONRIS in myelofibrosis and multiple myeloma. This prompted my desire to revisit this story to determine whether there's a near- to medium-term upside opportunity for readers to take advantage of.
Figure 1: STML daily advanced chart
(Source: Finviz)
When looking at charts, clarity